AnHorn Medicines Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $10M

  • Investors
  • 10

AnHorn Medicines General Information

Description

Manufacturer of an artificial intelligence-driven drug discovery platform designed to develop protein degraders and small-molecule therapeutics for dermatological conditions, cancer, cancer support, and neurodegenerative diseases. The company offers drug discovery capabilities focused on identifying candidates that target and degrade disease-related proteins, enabling pharmaceutical companies, researchers, and clinicians to develop treatments for serious diseases, including conditions affected by drug resistance.

Contact Information

Website
www.anhornmed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • National Biotechnology Research Park, Number 99, Lane 130, Section 1
  • Research Institute Road, Nangang District
  • Taipei, 115
  • Taiwan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Manufacturing, Life Sciences
Corporate Office
  • National Biotechnology Research Park, Number 99, Lane 130, Section 1
  • Research Institute Road, Nangang District
  • Taipei, 115
  • Taiwan

AnHorn Medicines Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AnHorn Medicines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 15-May-2025 $10M Completed Generating Revenue
3. Early Stage VC (Series A) 23-Dec-2022 Completed Generating Revenue
2. Accelerator/Incubator 01-May-2021 Completed Generating Revenue
1. Angel (individual) Completed Generating Revenue
To view AnHorn Medicines’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

AnHorn Medicines Patents

  • 15

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 11

    Pending

  • Expiring in next 12 mo

AnHorn Medicines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023296682-A1 Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same Pending 30-Jun-2022
EP-4547668-A1 Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same Pending 30-Jun-2022
EP-4547668-A4 Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same Pending 30-Jun-2022
US-20250197409-A1 Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same Pending 30-Jun-2022
US-20260248926-A1 Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same Pending 30-Jun-2022 A61K47/55
To view AnHorn Medicines’s complete patent history, request access »

AnHorn Medicines Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Black Marble Capital Management Venture Capital Minority
Hong Tai Electric Industrial Company Corporation Minority
Innovation Industrial Technology Transfer Corporate Venture Capital Minority
Maxpro Ventures Venture Capital Minority
Mega Venture Capital PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

AnHorn Medicines FAQs

  • When was AnHorn Medicines founded?

    AnHorn Medicines was founded in 2020.

  • Where is AnHorn Medicines headquartered?

    AnHorn Medicines is headquartered in Taipei, Taiwan.

  • What industry is AnHorn Medicines in?

    AnHorn Medicines’s primary industry is Drug Discovery.

  • Is AnHorn Medicines a private or public company?

    AnHorn Medicines is a Private company.

  • What is AnHorn Medicines’s current revenue?

    The current revenue for AnHorn Medicines is .

  • How much funding has AnHorn Medicines raised over time?

    AnHorn Medicines has raised $20M.

  • Who are AnHorn Medicines’s investors?

    Black Marble Capital Management, Hong Tai Electric Industrial Company, Innovation Industrial Technology Transfer, Maxpro Ventures, and Mega Venture Capital are 5 of 10 investors who have invested in AnHorn Medicines.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process